Differential Cardiovascular Outcomes of Each Antihypertensive Drug Class in Patients With Hypertension and Breast Cancer Undergoing Doxorubicin-Containing Chemotherapy
CONCLUSION: RAS inhibitors are preferred for the treating hypertension and improving CV outcomes in patients with hypertension and breast cancer undergoing DOX-containing chemotherapy, particularly in patients with comorbid diabetes. However, CCBs are equivalent to RAS inhibitors and are more favorable than BBs and TDs in terms of improving CV outcomes.PMID:37704380 | DOI:10.4048/jbc.2023.26.e34
Source: Journal of Breast Cancer - Category: Cancer & Oncology Authors: Hui-Jeong Hwang Sang-Ah Han Source Type: research
More News: Arrhythmia | Beta-Blockers | Breast Cancer | Calcium | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | Diabetes | Endocrinology | Heart | Heart Disease | Heart Failure | Hypertension | Insurance | Ischemic Stroke | Stroke | Study | Ventricular Tachycardia